SCHEMBL2276220

SCHEMBL2276220

CC(C)(C)OC(=O)c1ccc(Oc2ccccc2)cc1NC(=O)c1ccccc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.55
TDP1 Q9NUW8 1/20 0.55
LMNA P02545 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TLR8 Q9NR97 1/20 0.49
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
GAA P10253 2/20 0.47
HPGD P15428 1/20 0.47
KLF5 Q13887 1/20 0.46
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 1/20 0.43
PNLIP P16233 1/20 0.43
TP53 P04637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
MEN1 O00255 2/20 0.42
MAPK1 P28482 1/20 0.42
GFER P55789 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2271662 0.86 KMT2A (0.57) LMNANPSR1RAB9ANPC1GAA
SCHEMBL2275036 0.85 L3MBTL1 (0.64) L3MBTL1TDP1LMNANPSR1TLR8
SCHEMBL2269839 0.84 L3MBTL1 (0.46) L3MBTL1TDP1LMNANPSR1RAB9A
SCHEMBL2269667 0.82 F10 (0.53) NPSR1GAAHPGDALDH1A1KMT2A
SCHEMBL2270366 0.81 STK39 (0.47) L3MBTL1NPSR1TLR8ALDH1A1KMT2A
SCHEMBL2277873 0.81 PYGM (0.44) TDP1LMNAKMT2AKDM4EMEN1
SCHEMBL2269139 0.81 CYP2C9 (0.47) RAB9ANPC1HPGDALDH1A1KMT2A
SCHEMBL2275596 0.81 FABP1 (0.51) TDP1RAB9ANPC1ALDH1A1KMT2A
SCHEMBL2276375 0.80 GRIK1 (0.49) TDP1RAB9ANPC1KMT2AMEN1
SCHEMBL14428460 0.79 L3MBTL1 (0.60) L3MBTL1TDP1LMNANPSR1TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 L3MBTL1 3822/4885TDP1 3823/4885LMNA 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.